. It involved 157 patients with advanced melanoma who had their tumors completely surgically removed. These patients were randomly split into two groups who received treatment for about a year. One group was given regular infusions of Merck’s Keytruda, a lab-made antibody that helps immune cells better recognize and kill certain cancers. The other group was given Keytruda and nine doses in total of the vaccine candidate, called mRNA-4157/V940.
cancer returning on average than those who only received Keytruda . The vaccine in conjunction with Keytruda also appeared to reduce the combined risk of cancer recurrence and death by 44%.“Today’s results are highly encouraging for the field of cancer treatment.
We all need privacy, especially online. Your IP address and your browsing should be hidden from unecessary surveillance. Rest assured that PIA’s virtual private network never keeps any usage logs—ever.
Awesome news... But here comes the tinfoil hat-wearing bunker crew...
What’s the yellow check mark by your name?
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna's mRNA Skin Cancer Vaccine Shows Early Promise in a New StudyThe company reported encouraging results from a small study define success Success?!?! Are you nuts?! 'Success of its mRNA vaccine' The media party IS the enemy of the people.
Source: TIMEHealth - 🏆 121. / 63 Read more »
Moderna’s mRNA Cancer Vaccine Shows Promise in Preliminary StudyA customized Moderna vaccine combined with a Merck immunotherapy helped ward off the recurrence of skin cancer in people in a midstage trial Got to get rid of the overstock somehow Can You Really Eat Me Out!! I bet you'd be scared lol DM!! Like I believe this crap. Their Covid jab put my buddy in a wheelchair.
Source: WSJ - 🏆 98. / 63 Read more »
Experimental mRNA cancer vaccine with immunotherapy reduces risk of melanoma returning, preliminary study finds | CNNAn experimental personalized mRNA vaccine in combination with the immunotherapy Keytruda reduced the risk of recurrence or death from melanoma in patients who had already had surgery, Moderna and Merck said Tuesday. Non compro niente. Grazie That seems like a stretch but oookk The Islamic republic is about to execute MahanSadarat for the crime he has not committed, please help us to stop this inhumane ruling MahsaAmini MohsenShekari
Source: cnni - 🏆 326. / 59 Read more »
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial. Kind of convenient and good for NO BID PATENT PROFITS, that one jab causes a huge health problem, which can be 'solved' by another set of jabs, eh?
Source: Reuters - 🏆 2. / 97 Read more »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Source: wsfa12news - 🏆 338. / 59 Read more »
Merck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said. MRNA? Then obviously hell no. Who knows where those skin cancer proteins are headed. No thanks. Yeah, I’ll use sunscreen and get yearly skin checks. Btw, I’m a skin cancer survivor!
Source: FOX29philly - 🏆 570. / 51 Read more »